Navigation Links
Encorium Reports Second Quarter 2009 Financial Results
Date:8/24/2009

WAYNE, Pa., Aug. 24 /PRNewswire/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced its financial results for the second quarter ended June 30, 2009.

As previously announced, on July 16, 2009 the Company sold substantially all of the assets relating to its US line of business to Pierrel Research USA, Inc., the result of which the Company no longer has any employees or significant operations in the United States. Due to this sale, for the six months ended June 30, 2009 and 2008, the results of the U.S. business have been presented as discontinued operations in the Company's consolidated financial statements.

Net revenue for the second quarter of 2009 was $4.5 million, a decrease of 23.37% from $5.9 million for the second quarter of 2008. The decrease in net revenues was primarily attributable to unfavorable foreign currency fluctuations of $1.4 million for the three months ended June 30, 2009. The Company had a consolidated backlog at June 30, 2009 from continuing operations of $19.6 million which included approximately $4.8 million of new business wins in the first half of 2009 compared to a backlog of $23.5 million at June 30, 2008.

Direct expenses for the second quarter of 2009 were $3.4 million, or 76.3% of net revenues, compared to $3.8 million, or 64.2% of net revenues, for the comparable prior year period. The decrease in direct expenses was primarily the result of approximately $541,000 of favorable foreign currency fluctuations absorbed by the Company's European operations in the second quarter of 2009, partially offset
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
8. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
9. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. QMed, Inc. Reports July Medicare SNP Enrollments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... -- RXi Pharmaceuticals Corporation (NASDAQ: RXII ), a ... primarily in the areas of dermatology and ophthalmology, today ... million units at a price to the public of ... million. Each unit consists of (i) one share of ... purchase 0.50 of a share of common stock at ...
(Date:5/28/2015)... 2015  GenVec, Inc. (Nasdaq: GNVC ) today ... Swirsky , will present a company overview at the ... on Thursday, June 4, 2015. The ... be available at the following link:  http://wsw.com/webcast/jeff88/gnvc .  ... To access, visit www.genvec.com , click on "Investors ...
(Date:5/28/2015)... 28, 2015 The Fertility Centers of ... Dr. Danielle Vitiello has taken on a new and ... Vitiello will provide guidance, leadership, oversight and quality assurance ... Dr. Vitiello among our team of experienced reproductive endocrinologists,” ... Joseph A. Hill, M.D. “Her expertise and compassionate, individualized ...
(Date:5/28/2015)... NY (PRWEB) May 28, 2015 Whitehouse ... and enhanced its long term partnership with PTI Inspection ... together to provide clients with custom-tailored method development ... art instruments currently available. The agreement includes a more ... employees across organizational lines. This enables a more ...
Breaking Biology Technology:RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3
... in product ... identification, INDIANAPOLIS, ... announced the introduction of a color differentiation,system for U-100 insulin products ... Humalog(R) (insulin lispro,injection [rDNA origin]) and Humulin(R) (regular insulin human injection,USP ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... 1/2a study,demonstrating that repeat administration with TRU-015 ... in rheumatoid arthritis,(RA) signs and symptoms based ... also announced positive results following preliminary,analyses from ...
... Call at 8:30 a.m. Eastern Time Today to ... ... Inc. (Nasdaq: BCRX ) today announced results of an,exploratory Phase ... for acute serious or potentially,life-threatening influenza. The Phase 2 trial compared ...
Cached Biology Technology:Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 2Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 3Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 4Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 5Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 2BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 3BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 4BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 6
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... the University of Illinois at Chicago Institute for Health Research ... determine whether or not TV food advertising affects children,s diet, ... the National Cancer Institute, is unique because it will separate ... time that children watch TV. "A number of studies ...
... who live in industrialized countries have easy access to healthy ... That,s a problem because new research from Tel Aviv University ... memory, may be even more critical than previously thought for ... Begun at MIT, the research started as a part ...
... Thanks to the introduction of various non-native species to ... animals. A new application developed by ecologists at the ... issue of Methods in Ecology and Evolution , ... to improve the success of wildlife managers tasked with ...
Cached Biology News:Do TV ads affect children's diet, obesity? 2Remember magnesium if you want to remember 2Killing in the name of conservation 2
... The BD FACSAria cell sorter sets a ... Based on a revolutionary new design ... high-speed sorting and multicolor analysis. The BD ... that incorporates a fixed-alignment cuvette flow cell. ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
... antibody raised against a partial ... Immunogen: SF3B2 (NP_006833, 592 ... recombinant protein with GST tag. ... NM_006842 ...
Biology Products: